Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

被引：1340

作者：

Vaduganathan, Muthiah ^{[1
,2
]}

Vardeny, Orly ^{[3
,4
]}

Michel, Thomas ^{[1
,2
]}

McMurray, John J., V ^{[5
]}

Pfeffer, Marc A. ^{[1
,2
]}

Solomon, Scott D. ^{[1
,2
]}

机构：

[1] Brigham & Womens Hosp, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA

[2] Harvard Med Sch, Boston, MA 02115 USA

[3] Minneapolis VA Hlth Care Syst, Ctr Care Delivery & Outcomes Res, Minneapolis, MN USA

[4] Univ Minnesota, Minneapolis, MN USA

[5] Univ Glasgow, Cardiovasc Res Ctr, British Heart Fdn, Glasgow, Lanark, Scotland

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 382卷 / 17期

关键词：

CONVERTING ENZYME 2; EXPERIMENTAL AUTOIMMUNE MYOCARDITIS; SARS-CORONAVIRUS; HEART-FAILURE; HYPERTENSIVE PATIENTS; FUNCTIONAL RECEPTOR; ACE2; EXPRESSION; DOWN-REGULATION; MODULATION; OLMESARTAN;

D O I：

10.1056/NEJMsr2005760

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The effects of renin-angiotensin-aldosterone system blockers on angiotensin-converting enzyme 2 levels and activity in humans are uncertain. The authors hypothesize that ACE2 may be beneficial rather than harmful during lung injury and suggest that RAAS-inhibitor withdrawal may be harmful in some high-risk patients with known or suspected Covid-19.

引用

页码：1653 / 1659

页数：7

共 68 条

[1] Characteristics and outcome of viral pneumonia caused by influenza and Middle East respiratory syndrome-coronavirus infections: A 4-year experience from a tertiary care center [J].